Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| California Walnut Growers Association | UNKNOWN |
| C.H.O. American, Natural and Organic Olive Oil Producer Association | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
This study is designed to test the feasibility of asking older adults with high blood pressure to supplement their daily diets with walnuts and extra-virgin olive oil.
Even though cardiovascular disease (CVD) continues to be the leading cause of death in the United States, Americans have yet to widely adopt evidence-based dietary modifications necessary to reduce CVD risk factors. Encouraging evidence from the Prevención con Dieta Mediterránea (PREDIMED) trial indicates that adding olive oil and nuts to the diets of older adults in Spain substantially impacted CVD risk factors and events.
A large trial testing EVOO and nuts in a U.S. population is needed to determine if supplementing with EVOO and nuts can reduce risk of cardiovascular events and mortality in adults living in the U.S. Prior to launching a large trial, it is important to assess whether adults 55 and older would be interested in participating in a supplementation trial such as PREDIMED. Additionally, it is important to assess if they are willing to consume the nuts and EVOO and attend study related-data collection visits.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention | Experimental | All participants will receive an 8-week supply of walnuts and Extra Virgin Olive Oil (EVOO). Study supplements will consist of 28 gm of walnuts and 32 gm of EVOO per day. Participants will be instructed how to consume the proper amount of walnuts and EVOO and to report their consumption using a compliance diary. The walnuts are pre-packaged in daily servings (one 28 g packet per day) and measuring spoons will be provided with the olive oil to assist participants in consuming it appropriately. Participants will also receive recipes and other written information that will assist them in incorporating both the nuts and olive oil into their existing dietary patterns. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Walnuts | Dietary Supplement | 28 gm/day in single-serve package |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Retention of study participants | To estimate retention (measured by number attending the 8 week closeout visit) of men and women being treated for hypertension in the 8 week study. | 8 weeks |
| Adherence to consuming walnuts and EVOO | To assess adherence to consuming the nut and oil supplements (measured by daily diary of supplement intake) over the course of the study. | 8 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Blood pressure | To estimate the variability of blood pressure in men and women participating in the study | 8 weeks |
| Weight | To estimate the variability of weight in men and women participating in the study |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mara Z Vitolins, DrPH MPH RDN | Wake Forest University Health Sciences | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006973 | Hypertension |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Extra Virgin Olive Oil |
| Dietary Supplement |
32 gm/day provided in 3, 34 ounce bottles |
|
| 8 weeks |
| HDL cholesterol | To estimate the variability of HDL cholesterol in men and women participating in the study | 8 weeks |
| Adverse events | To document the types and the rates of adverse events associated with the supplements. | 8 weeks |